Detection of CFTR function and modulation in primary human nasal cell spheroids

Journal of Cystic Fibrosis

Volumn 17, Issue 1, 2018, Pages 26-33

  Brewington, John J ^a   Filbrandt, Erin T ^a   LaRosa, F J ^a   Ostmann, Alicia J ^a   Strecker, Lauren M ^a   Szczesniak, Rhonda D ^a   Clancy, John P ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

CFTR; Modulator; Organoid; Personalized model system

Indexed keywords

CYCLIC AMP; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FORSKOLIN; ISOBUTYLMETHYLXANTHINE; CHLORIDE CHANNEL STIMULATING AGENT; EPITHELIAL SODIUM CHANNEL;

ADOLESCENT; ADULT; ARTICLE; CELL CULTURE; CELL GROWTH; CELL SWELLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CURETTAGE; CYSTIC FIBROSIS; EPITHELIUM CELL; HUMAN; HUMAN CELL; NASAL EPITHELIAL CELL; NOSE; PROTEIN FUNCTION; RESPIRATORY EPITHELIUM; SPHEROID CELL; CELL CULTURE TECHNIQUE; FEMALE; GENETICS; INFANT; MALE; METABOLISM; MUTATION; NOSE MUCOSA; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES;

ADOLESCENT; ADULT; CELL CULTURE TECHNIQUES; CHILD; CHILD, PRESCHOOL; CHLORIDE CHANNEL AGONISTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL SODIUM CHANNELS; FEMALE; HUMANS; INFANT; MALE; MUTATION; NASAL MUCOSA;

EID: 85023636928     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2017.06.010     Document Type: Article

References (24)

1. Rowe, S.M., Miller, S., Sorscher, E.J., Cystic fibrosis. N Engl J Med 352:19 (2005), 1992–2001.
2. Pilewski, J.M., Frizzell, R.A., Role of CFTR in airway disease. Physiol Rev 79:1 Suppl (1999), S215–S255.
3. Welsh, M.J., An apical-membrane chloride channel in human tracheal epithelium. Science 232:4758 (1986), 1648–1650.
4. Schwiebert, E.M., Benos, D.J., Egan, M.E., Stutts, M.J., Guggino, W.B., CFTR is a conductance regulator as well as a chloride channel. Physiol Rev 79:1 Suppl (1999), S145–S166.
5. CFF JHM, CFTR2 database 2015 [2/4/2016]. Available from: www.cftr2.org.
6. Boucher, R.C., Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 261:1 (2007), 5–16.
7. Boyle, M.P., Bell, S.C., Konstan, M.W., McColley, S.A., Rowe, S.M., Rietschel, E., et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2:7 (2014), 527–538.
8. Clancy, J.P., Rowe, S.M., Accurso, F.J., Aitken, M.L., Amin, R.S., Ashlock, M.A., et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67:1 (2012), 12–18.
9. Ramsey, B.W., Davies, J., McElvaney, N.G., Tullis, E., Bell, S.C., Drevinek, P., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365:18 (2011), 1663–1672.
10. Wainwright, C.E., Elborn, J.S., Ramsey, B.W., Marigowda, G., Huang, X., Cipolli, M., et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med, 2015.
11. Boinot, C., Jollivet Souchet, M., Ferru-Clement, R., Becq, F., Searching for combinations of small-molecule correctors to restore f508del-cystic fibrosis transmembrane conductance regulator function and processing. J Pharmacol Exp Ther 350:3 (2014), 624–634.
12. Treatment with VX-661 and ivacaftor in a phase 2 study resulted in statistically significant improvements in lung function in people with cystic fibrosis who have two copies of the F508del mutation [press release]. 4/18/2013.
13. Phuan, P.W., Veit, G., Tan, J., Finkbeiner, W.E., Lukacs, G.L., Verkman, A.S., Potentiators of defective DeltaF508-CFTR channel gating that do not interfere with corrector action. Mol Pharmacol, 2015.
14. Van Goor, F., Hadida, S., Grootenhuis, P.D., Burton, B., Stack, J.H., Straley, K.S., et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 108:46 (2011), 18843–18848.
15. Neuberger, T., Burton, B., Clark, H., Van Goor, F., Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators. Methods Mol Biol 741 (2011), 39–54.
16. Liu, X., Ory, V., Chapman, S., Yuan, H., Albanese, C., Kallakury, B., et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 180:2 (2012), 599–607.
17. Mou, H., Brazauskas, K., Rajagopal, J., Personalized medicine for cystic fibrosis: establishing human model systems. Pediatr Pulmonol 50:Suppl. 40 (2015), S14–S23.
18. Dekkers, J.F., Wiegerinck, C.L., de Jonge, H.R., Bronsveld, I., Janssens, H.M., de Winter-de Groot, K.M., et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med 19:7 (2013), 939–945.
19. Dekkers, R., Vijftigschild, L.A., Vonk, A.M., Kruisselbrink, E., de Winter-de Groot, K.M., Janssens, H.M., et al. A bioassay using intestinal organoids to measure CFTR modulators in human plasma. J Cyst Fibros 14:2 (2015), 178–181.
20. Clancy, J.P., Szczesniak, R.D., Ashlock, M.A., Ernst, S.E., Fan, L., Hornick, D.B., et al. Multicenter intestinal current measurements in rectal biopsies from CF and non-CF subjects to monitor CFTR function. PLoS One, 8(9), 2013, e73905.
21. Pedersen, P.S., Frederiksen, O., Holstein-Rathlou, N.H., Larsen, P.L., Qvortrup, K., Ion transport in epithelial spheroids derived from human airway cells. Am J Physiol 276:1 Pt 1 (1999), L75–L80.
22. Bridges, M.A., Walker, D.C., Harris, R.A., Wilson, B.R., Davidson, A.G., Cultured human nasal epithelial multicellular spheroids: polar cyst-like model tissues. Biochem Cell Biol 69:2–3 (1991), 102–108.
23. Wu, X., Mimms, R., Banigan, M., Lee, M., Elkis, V., Peters-Hall, J.R., et al. Development of glandular models from human nasal progenitor cells. Am J Respir Cell Mol Biol 52:5 (2014), 535–542.
24. Denning, G.M., Anderson, M.P., Amara, J.F., Marshall, J., Smith, A.E., Welsh, M.J., Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358:6389 (1992), 761–764.